BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35266680)

  • 1. Clinical study of apatinib mesylate combined with paclitaxel injection and cisplatin injection in the treatment of non-small cell lung cancer.
    Li F; You H; Chen L; Zou A; Mao Y
    Minerva Surg; 2023 Apr; 78(2):235-237. PubMed ID: 35266680
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis.
    Li Z; Liu Z; Wu Y; Li H; Sun Z; Han C; Zhang X; Zhang J
    Thorac Cancer; 2021 Nov; 12(21):2838-2848. PubMed ID: 34622571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer.
    Sculier JP; Lafitte JJ; Lecomte J; Alexopoulos CG; Van Cutsem O; Giner V; Efremidis A; Berchier MC; Collon T; Meert AP; Scherpereel A; Ninane V; Paesmans M; Berghmans T;
    Ann Oncol; 2007 Jun; 18(6):1037-42. PubMed ID: 17404152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A randomized trial of liposomal paclitaxel plus cisplatin as first-line therapy for advanced non-small cell lung cancer].
    Yang X; Zhang H; Nong J; Wang J; Li X; Zhang Q; Wang Q; Gao Y; Zhang S
    Zhongguo Fei Ai Za Zhi; 2012 Apr; 15(4):208-12. PubMed ID: 22510505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly.
    Chen YM; Perng RP; Tsai CM; Whang-Peng J
    J Thorac Oncol; 2006 Feb; 1(2):141-5. PubMed ID: 17409843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Hayashi H; Ogura M; Niwa T; Yokoyama T; Tanizaki J; Ozaki T; Yoshioka H; Kurata T; Tamura Y; Fujisaka Y; Tanaka K; Hasegawa Y; Kudo K; Chiba Y; Nakagawa K
    Oncologist; 2021 Jan; 26(1):19-e52. PubMed ID: 32918791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Clinical Efficacy of Nano-Albumin Paclitaxel Treatment for Advanced Cell Lung Cancer.
    Li X; Zhang Y; Zhi X; Li Y; Qian K
    J Nanosci Nanotechnol; 2020 Oct; 20(10):6019-6025. PubMed ID: 32384947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prediction of a non-small cell lung cancer sensitivity to cisplatin and paclitaxel based on the marker genes expression].
    Boiarskikh UA; Kondrakhin IuV; Evshin IS; Sharipov RN; Komel'kov AV; Musatkina EA; Chevkina EM; Sukoian MA; Kolpakov FA; Kashkin KN; Filipenko ML
    Mol Biol (Mosk); 2011; 45(4):652-61. PubMed ID: 21954597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.
    Berghmans T; Lafitte JJ; Lecomte J; Alexopoulos CG; Van Cutsem O; Giner V; Efremidis A; Berchier MC; Collon T; Meert AP; Scherpereel A; Ninane V; Leclercq N; Paesmans M; Sculier JP;
    Br J Cancer; 2007 Jun; 96(11):1644-9. PubMed ID: 17473825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL; Hurst M
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.
    Gatzemeier U; von Pawel J; Gottfried M; ten Velde GP; Mattson K; de Marinis F; Harper P; Salvati F; Robinet G; Lucenti A; Bogaerts J; Gallant G
    J Clin Oncol; 2000 Oct; 18(19):3390-9. PubMed ID: 11013280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is cisplatin still the best platinum compound in non-small-cell lung cancer?
    Soria JC; Le Chevalier T
    Ann Oncol; 2002 Oct; 13(10):1515-7. PubMed ID: 12377638
    [No Abstract]   [Full Text] [Related]  

  • 15. PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Jung DK; Choi JE; Jin CC; Hong MJ; Do SK; Kang HG; Lee WK; Seok Y; Lee EB; Jeong JY; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Sci Rep; 2016 May; 6():25952. PubMed ID: 27181838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
    Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
    Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer.
    Novello S; Le Chevalier T
    Semin Oncol; 2001 Aug; 28(4 Suppl 14):3-9. PubMed ID: 11605176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study on the efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced stage non-small cell lung cancer.
    Zhao J; Yu H; Han T; Wang W; Tong W; Zhu X
    J BUON; 2019; 24(6):2267-2272. PubMed ID: 31983093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer.
    Subhani S; Jayaraman A; Jamil K
    Biomed Pharmacother; 2015 Apr; 71():37-45. PubMed ID: 25960213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.